SEARCH

SEARCH BY CITATION

References

  • Avila MA, Mingorance J, Martinez-Chantar ML, Casado M, Martin-Sanz P, Bosca L, Mato JM (1997) Regulation of rat liver S-adenosylmethionine synthetase during septic shock: role of nitric oxide. Hepatology 25, 391396.
  • Avila MA, Corrales FJ, Ruiz F, Sanchez-Gongora E, Mingorance J, Carretero MV, Mato IM (1998) Specific interaction of methionine adenosyltransferase with free radicals. Biofactors 8, 2732.
  • Bates DE (2003) Aminoglycoside ototoxicity. Drugs Today (Barc) 39, 277285.
  • Biegon A, Alvarado M, Budinger TF, Grossman R, Hensley K, West MS, Kotake Y, Ono M, Floyd RA (2002) Region-selective effects of neuroinflammation and antioxidant treatment on peripheral benzodiazepine receptors and NMDA receptors in the rat brain. J. Neurochem. 82, 924934.
  • Canlon B, Erichsen S, Nemlander E, Chen M, Hossain A, Celsi G, Ceccatelli S (2003) Alterations in the intrauterine environment by glucocorticoids modifies the developmental programme of the auditory system. Eur. J. Neurosci. 17, 20352041.
  • Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA 96, 42404245.
  • Carney JM, Floyd RA (1991) Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage. [U.S. Patent # 5,025,032 Filed: 10-07-89]. 1-18-1991. Ref Type: Patent.
  • Carney JM, Starke-Reed PE, Oliver CN, Landrum RW, Chen MS, Wu JF, Floyd RA (1991) Reversal of age-related increase in brain protein oxidation, decrease in enzyme activity, and loss in temporal and spacial memory by chronic administration of the spin-trapping compound N-tert-butyl-α-phenylnitrone. Proc. Natl Acad. Sci. USA 88, 36333636.
  • Castro C, Ruiz FA, Perez-Mato I, Sanchez del Pino MM, LeGros L, Geller AM, Kotb M, Corrales FJ, Mato JM (1999) Creation of a functional S-nitrosylation site in vitro by single point mutation. FEBS Lett. 459, 319322.
  • Corrales FJ, Perez-Mato I, Sanchez del Pino MM, Ruiz F, Castro C, Garcia-Trevijano ER, Latasa U, Martinez-Chantar ML, Martinez-Cruz A, Avila MA, Mato JM (2002) Regulation of mammalian liver methionine adenosyltransferase. J. Nutr 132, 2377S2381S.
  • Edamatsu R, Mori A, Packer L (1995) The spin-trap N-tert-α-phenyl-butylnitrone prolongs the life span of the senescence accelerated mouse. Biochem. Biophys. Res. Commun. 211, 847849.
  • Fechter LD, Gearhart C, Shirwany NA (2004) Acrylonitrile potentiates noise-induced hearing loss in rat. J. Assoc. Res. Otolaryngol. 5, 9098.
  • Fechter LD, Liu Y, Pearce TA (1997) Cochlear protection from carbon monoxide exposure by free radical blockers in the guinea pig. Toxicol. Appl. Pharmacol. 142, 4755.
  • Floyd RA (1990) Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J. 4, 25872597.
  • Floyd RA (1997) Protective action of nitrone-based free radical traps against oxidative damage to the central nervous system. Adv. Pharmacol. 38, 361378.
  • Floyd RA (1999a) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222, 236245.
  • Floyd RA (1999b) Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic. Biol. Med. 26, 13461355.
  • Floyd RA, Carney JM (1992) Protection against oxidative damage to CNS by α-phenyl-tert-butyl nitrone and other spin-trapping agents: a novel series of nonlipid free radical scavengers. In: Emerging Strategies in Neuroprotection (MarangosPJ, LalH, eds). Boston, Basel, Berlin: Birkhauser, pp. 252272.
  • Floyd RA, Hensley K, Bing G (2000) Evidence for enhanced neuro-inflammatory processes in neurodegenerative diseases and the action of nitrones as potential therapeutics. J. Neural Trans. 60, 337364.
  • Floyd RA, Hensley K, Forster MJ, Kelleher-Anderson JA, Wood PL (2001) Nitrones, their value as therapeutics and probes to understand aging. Mech. Ageing Dev. 123, 10211031.
  • Floyd RA, Hensley K, Forster MJ, Kelleher-Anderson JA, Wood PL (2002a) Nitrones as neuroprotectants and antiaging drugs. Ann. N Y Acad. Sci. 959, 321329.
  • Floyd RA, Kotake Y, Hensley K, Nakae D, Konishi Y (2002b) Reactive oxygen species in choline deficiency induced carcinogenesis and nitrone inhibition. Mol. Cell. Biochem. 234/235, 195203.
  • Green AR, Ashwood T (2005) Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. Curr. Drug Targets CNS Neurol. Disord. 4, 109118.
  • Green AR, Ashwood T, Odergren T, Jackson DM (2003) Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059. Pharmacol. Ther. 100, 195214.
  • Jaiswal M, LaRusso NF, Nishioka N, Nakabeppu Y, Gores GJ (2001) Human Ogg1, a protein involved in the repair of 8-oxoguanine, is inhibited by nitric oxide. Cancer Res. 61, 63886393.
  • Kim YM, Talanian RV, Billiar TR (1997a) Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J. Biol. Chem. 272, 3113831148.
  • Kim Y-M, DeVera ME, Watkins SC, Billiar TR (1997b) Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-α-induced apoptosis by inducing heat shock protein 70 expression. J. Biol. Chem. 272, 14021411.
  • Kim YM, Kim TH, Chung HT, Talanian RV, Yin XM, Billiar TR (2000) Nitric oxide prevents tumor necrosis factor alpha-induced rat hepatocyte apoptosis by the interruption of mitochondrial apoptotic signaling through S-nitrosylation of caspase-8. Hepatology 32, 770778.
  • Kotake Y, Moore DR, Sang H, Reinke LA (1999) Continuous monitoring of in vivo nitric oxide formation using EPR analysis in biliary flow. Nitric Oxide: Biol. Chem. 3, 114122.
  • Kotake Y, Kishida H, Nakae D, Floyd RA (2005) Nitric oxide production by primary liver cells isolated from amino acid diet fed rats. Methods Enzymol. 396, 535541.
  • Kuroda S, Tsuchidate R, Smith M-L, Maples KR, Siesjo BK (1999) Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J. Cereb Blood Flow Metab 19, 778787.
  • Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng Y-F, Odergren T, SA-NXY-0003 Investigators (2001) Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Stroke 32, 675680.
  • Lees KR, Barer D, Ford GA, Hacke W, Kostulas V, Sharma AK, Odergren T, SA-NXY-0003 Investigators (2003) Tolerability of NXY-059 at higher target concentrations in patients with acute stroke. Stroke 34, 482487.
  • Maples KR, Green AR, Floyd RA (2004) Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke. CNS Drugs 18, 10711084.
  • Marshall JWB, Duffin KJ, Green AR, Ridley RM (2001) NXY-059, A free radical-trapping agent, substantially lessens the functional disability resultying from cerebral ischemia in a primate species. Stroke 32, 190198.
  • Marshall JW, Cummings RM, Bowes LJ, Ridley RM, Green AR (2003) Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 34, 22282233.
  • Nakae D, Kotake Y, Kishida H, Hensley KL, Denda A, Kobayashi Y, Kitayama W, Tsujiuchi T, Sang H, Stewart CA, Tabatabaie T, Floyd RA, Konishi Y (1998) Inhibition by phenyl N-tert-butyl nitrone on early phase carcinogenesis in the livers of rats fed a choline-deficient, L-amino acid-defined diet. Cancer Res. 58, 45484551.
  • Nakae D, Kishida H, Enami T, Konishi Y, Hensley KL, Floyd RA, Kotake Y (2003) Effects of phenyl N-tert-butyl nitrone and its derivatives on the early phase of hepatocarcinogenesis in rats fed a choline-deficient, 1-amino acid-defined diet. Cancer Sci. 94, 2631.
  • Nakae D, Uematsu F, Kishida H, Kusuoka O, Katsuda S, Yoshida M, Takahashi M, Maekawa A, Denda A, Konishi Y, Kotake Y, Floyd RA (2004) Inhibition of the development of hepatocellular carcinomas by phenyl N-tert-butyl nitrone in rats fed with a choline-deficient, L-amino acid-defined diet. Cancer Lett. 206, 113.
  • Perez-Mato I, Castro C, Ruiz FA, Corrales FJ, Mato JM (1999) Methionine adenosyltransferase S-nitrosylation is regulated by the basic and acidic amino acids surrounding the target thiol. J. Biol. Chem. 274, 1707517079.
  • Radisavljevic Z (2003) Nitric oxide suppression triggers apoptosis through the FKHRL1 (FOXO3A)/ROCK kinase pathway in human breast carcinoma cells. Cancer 97, 13581363.
  • Ranchon I, Chen S, Alvarez K, Anderson RE (2001) Systemic administration of phenyl-n-tert-butylnitrone protects the retina from light damage. Invest Ophthalmol. Vis Sci. 42, 13751379.
  • Ranchon I, LaVail MM, Kotake Y, Anderson RE (2003) Free radical trap phenyl-N-tert-butylnitrone protects against light damage but does not rescue P23H and S334ter rhodopsin transgenic rats from inherited retinal degeneration. J. Neurosci. 23, 60506057.
  • Rao D, Fechter LD (2000) Protective effects of phenyl-N-tert-butylnitrone on the potentiation of noice-induced hearing loss by carbon monoxide. Toxicol. Appl. Pharmacol. 167, 125131.
  • Ruiz F, Corrales FJ, Miqueo C, Mato JM (1998) Nitric oxide inactivates rat hepatic methionine adenosyltransferase in vivo by S-nitrosylation. Hepatology 28, 10511057.
  • Sack CA, Socci DJ, Crandall BM, Arendash GW (1996) Antioxidant treatment with phenyl-α-tert-butyl nitrone (PBN) improves the cognitive performance and survival of aging rats. Neurosci. Lett. 205, 181184.
  • Saito K, Yoshioka H, Cutler RG (1998) A spin trap, N-tert-butyl-α-phenylnitrone extends the life span of mice. Biosci. Biotechnol. Biochem. 62, 792794.
  • Salvucci O, Carsana M, Bersani I, Tragni G, Anichini A (2001) Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res. 61, 318326.
  • Strid S, Borga O, Edenius C, Jostell K-G, Odergren T, Weil A (2002) Pharmacolinetics in renally impaired subjects of NXY-059, a nitrone-based, free-raidical trapping agent developed for the treatment of acute stroke. Eur J. Clin. Pharmacol. 58, 409415.
  • Sydserff SG, Borelli AR, Green AR, Cross AJ (2002) Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br. J. Pharmacol. 135, 103112.
  • Tomita H, Kotake Y, Anderson RE (2005) Mechanism of protection from light-induced retinal degeneration by the synthetic antioxidant phenyl-N-tert-butylnitrone. Invest Ophthalmol. Vis Sci. 46, 427434.
  • Torok NJ, Higuchi H, Bronk S, Gores GJ (2002) Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylating caspase 9. Cancer Res. 62, 16481653.
  • Yoshimoto T, Kanakaraj P, Ma JY, Cheng M, Kerr I, Malaiyandi L, Watson JA, Siesjo BK, Maples KR (2002) NXY-059 maintains Akt activation and inhibits release of cytochrome C after focal cerebral ischema. Brain Res. 947, 191198.